{
    "nctId": "NCT01725386",
    "briefTitle": "An Observational Study of Xeloda (Capecitabine) in Participants With Metastatic or Advanced Breast Cancer",
    "officialTitle": "Study on Xeloda\u00ae to Document Its Use in Routine Practice in Patients With Metastatic or Advanced Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 274,
    "primaryOutcomeMeasure": "Percent of Participants With Capecitabine as a First Line, Second Line, or Third Line Therapy",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Adult female participants, \\>/= 18 years of age\n* Cytologic/histopathologic confirmed diagnosis of metastatic breast cancer\n* Prescribed capecitabine as in routine clinical practice\n* Informed consent signed\n\nExclusion Criteria:\n\n* Participation in any other clinical trial\n* History of severe and unexpected reactions to fluoropyrimidine therapy\n* Hypersensitivity to capecitabine or to any of the excipients of fluorouracil\n* Known dihydropyrimidine dehydrogenase (DPD) deficiency\n* Pregnant or lactating women\n* Severe leucopenia, neutropenia, or thrombocytopenia\n* Severe hepatic impairment\n* Severe renal impairment (creatinine clearance below 30 ml/min)\n* Treatment with sorivudine or its chemically related analogues, such as brivudine\n* Refusal to give consent",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}